<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880785</url>
  </required_header>
  <id_info>
    <org_study_id>GESIDA11820</org_study_id>
    <nct_id>NCT04880785</nct_id>
  </id_info>
  <brief_title>Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine</brief_title>
  <acronym>VOLVER</acronym>
  <official_title>Virologic Outcomes of Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion SEIMC-GESIDA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion SEIMC-GESIDA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dolutegravir (DTG) plus lamivudine (3TC) is a dual regimen combination recommended for both&#xD;
      naïve and suppressed persons with HIV-1 infection1. However, data regarding the efficacy of&#xD;
      this regimen in suppressed persons with history of past resistance or virologic failures is&#xD;
      currently insufficient. This is a phase IIa, open-label, single arm, multicentric study.&#xD;
&#xD;
      The hypothesis is that therapy with DTG/3TC would be able to maintain viral control in HIV&#xD;
      infected participants with prior history of 3TC resistance but without evidence of M184V/I&#xD;
      resistance mutation in proviral DNA population sequencing at baseline. The investigators also&#xD;
      hypothesize that archived minority 3TC resistance associated mutations detected by&#xD;
      next-generation (NGS) sequencing prior to the switch would not have a significant impact on&#xD;
      the efficacy of DTG/3TC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentre study, and it will be conducted at different healthcare centres in&#xD;
      Spain. 117 participants will be recruited. A minimum of 30%-50% of the study population would&#xD;
      be required to have historical RNA population genotype with confirmed M184V/I mutation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase IIa, open-label, single arm, multicentric study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy of a switch to DTG/3TC for maintenance of virologic suppression, in persons with past confirmed or suspected 3TC resistance, when proviral DNA population sequencing does not detect 3TC resistance-associated mutations at baseline.</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of virologic failure (VF) defined as HIV-1 RNA viral load (VL) ≥ 50 copies per mL (in the intention-to-treatexposed population (ITT-e) using the US Food and Drug Administration (FDA) snapshot algorithm).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimations of virological control</measure>
    <time_frame>Week 48 and week 96</time_frame>
    <description>Proportion of VF (≥50 copies/mL) ITT-e, per protocol population (PP), Proportion of VF (≥200 copies/mL), ITT-e and PP population, FDA snapshot. Proportion of Confirmed Virologic Withdrawal ([CVW]: A VL≥ 50 copies/mL followed by a VL≥ 200 copies/mL in retest), ITT-e and PP population, FDA snapshot. Proportion of Precautionary Virologic Withdrawal ([PVW]: three consecutive VL between 50- 200 copies/mL), ITT-e and PP population, FDA snapshot. Proportion of participants with VL&lt;50 copies/mL, ITT-e and per protocol population, FDA snapshot.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral resistance in persons experiencing VF.</measure>
    <time_frame>Throughout all the study, an average of 96 weeks</time_frame>
    <description>Incidence of VF with drug resistance associated mutations.&#xD;
- Describe number and type of resistanceassociated mutations in VF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to VF</measure>
    <time_frame>Throughout all the study, an average of 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of VF in subgroups: Confirmed historical M184V/I vs No resistance mutations</measure>
    <time_frame>Throughout all the study, an average of 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of VF in subgroups: INSTI exposure vs No prior INSTI exposure</measure>
    <time_frame>Throughout all the study, an average of 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time virologically suppressed</measure>
    <time_frame>Throughout all the study, an average of 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of VF in subgroup: Time on 3TC/FTC</measure>
    <time_frame>Throughout all the study, an average of 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with VF with baseline 3TC or INSTI resistanceassociated mutations detected at baseline by NGS with 1, 5, and 20% threshold.</measure>
    <time_frame>Throughout all the study, an average of 96 weeks</time_frame>
    <description>Proportion of participants with transient viral rebounds with baseline 3TC or INSTI resistance- associated mutations detected at baseline by NGS with 1, 5, and 20% threshold.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with transient viral rebounds with baseline 3TC or INSTI resistance- associated mutations detected at baseline by NGS with 1, 5, and 20% threshold.</measure>
    <time_frame>Throughout all the study, an average of 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of resistance mutations (RT and integrase) in proviral DNA measured by NGS.</measure>
    <time_frame>Throughout all the study, an average of 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of resistance mutations (RT and integrase) in proviral DNA measured by NGS.</measure>
    <time_frame>Throughout all the study, an average of 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+ cell count</measure>
    <time_frame>Basal, Week 48 and week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+/CD8+ cell counts ratio</measure>
    <time_frame>Basal, Week 48 and week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of AEs and laboratory abnormalities.</measure>
    <time_frame>Basal, Week 48 and week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who discontinue treatment due to AEs</measure>
    <time_frame>Basal, week 48 and week 96</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">117</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Dovato (Dolutegravir+lamivudine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment: Dolutegravir 50 mg/Lamivudine 300 mg, one film coated-tablet once daily during 96 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato]</intervention_name>
    <description>change of current antiretroviral treatment to DTG 50 mg/3TC 300 mg QD</description>
    <arm_group_label>Dovato (Dolutegravir+lamivudine)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults (&gt;=18 years old) with HIV-1 infection able to understand and give informed&#xD;
             written consent.&#xD;
&#xD;
          2. Stable ART in the 12 weeks prior to screening visit.&#xD;
&#xD;
             - Only switch for tolerability/convenience/access reasons to generic drugs or switch&#xD;
             from ritonavir to cobicistat or TDF to TAF would be allowed in the 12-week window and&#xD;
             as long as the components of the regimen are unchanged.&#xD;
&#xD;
          3. Viral load &lt;50 copies/mL at screening and in the year prior to study entry.&#xD;
&#xD;
             - A blip (50-500 copies/ml) would be allowed within 48 weeks prior to inclusion in the&#xD;
             study, if preceded and followed by an undetectable VL determination.&#xD;
&#xD;
          4. CD4 count &gt; 200 cel/μL at screening.&#xD;
&#xD;
          5. History of 3TC resistance: either confirmed historical 3TC resistance (historical RNA&#xD;
             Sanger or RNA NGS&gt;20% threshold genotype with M184V/I mutation) OR suspected&#xD;
             historical 3TC resistance.&#xD;
&#xD;
               -  Suspicion of past 3TC resistance is defined as any of the following:&#xD;
&#xD;
        i. Previous treatment with only 2 NRTIs (1 of them being emtricitabine or 3TC [XTC]).&#xD;
&#xD;
        ii. Two consecutive VL &gt; 200 cp/mL while on treatment including XTC. iii. One VL &gt; 200&#xD;
        cp/mL while on treatment including XTC PLUS change of ART as consequence of that elevated&#xD;
        VL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants with M184V/I or K65R in screening visit proviral DNA Sanger genotype.&#xD;
&#xD;
          2. Prior virologic failure (VF) under integrase inhibitor (INSTI)- based regimen. defined&#xD;
             as two consecutive VL &gt; 200 copies/mL while receiving INSTI regardless of genotypic&#xD;
             test results&#xD;
&#xD;
          3. INSTI resistance mutations in historical RNA genotype.&#xD;
&#xD;
          4. Positive Surface Hepatitis B Ag (HBAgS) OR negative HBAgS and negative hepatitis B&#xD;
             surface antibody (anti-HBs) with positive anti-core antibody (anti-HBc) and positive&#xD;
             HBV DNA.&#xD;
&#xD;
          5. Pregnant, breastfeeding women, women with a positive pregnancy test at the time of&#xD;
             screening, sexually active fertile women wishing to conceive or unwilling to commit to&#xD;
             contraceptive methods (see Appendix 1 for the accepted list of the highly effective&#xD;
             methods for avoiding pregnancy), for the duration of the study and until 4 weeks after&#xD;
             the last dose of study medication. All women are considered fertile unless they have&#xD;
             undergone a sterilizing surgery or are over the age of 50 with spontaneous amenorrhea&#xD;
             for over 12 months prior to study entry.&#xD;
&#xD;
          6. Patients with active opportunistic infections or cancer requiring intravenous&#xD;
             treatment and/or chemotherapy at screening.&#xD;
&#xD;
          7. Any comorbidities or treatment with experimental drugs that according to the&#xD;
             investigator could bias study results or entail additional risks for the participant.&#xD;
&#xD;
          8. Participants receiving other medications that according to study drug label are&#xD;
             contraindicated.&#xD;
&#xD;
          9. Severe hepatic impairment (Class C) as determined by Child-Pugh classification.&#xD;
&#xD;
         10. Alanine aminotransferase (ALT) over 5 times the upper limit of normal (ULN) or ALT&#xD;
             over 3xULN and bilirubin over 1.5xULN.&#xD;
&#xD;
         11. Unstable liver disease (as defined by the presence of ascites, encephalopathy,&#xD;
             coagulopathy, hypoalbuminemia, oesophageal or gastric varices, or persistent&#xD;
             jaundice), cirrhosis, known biliary abnormalities (apart from hyperbilirubinemia or&#xD;
             jaundice due to Gilbert's syndrome or asymptomatic gallstones);&#xD;
&#xD;
         12. Creatinine clearance of &lt;30 mL/min/1.73m2 via CKD-EPI method.&#xD;
&#xD;
         13. Any verified Grade 4 laboratory abnormality that to the investigators criteria would&#xD;
             affect the safety of the participant if included in the study.&#xD;
&#xD;
         14. History or presence of allergy to dolutegravir or lamivudine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maria Yllescas, PhD</last_name>
    <phone>0034 915568025</phone>
    <email>myllescas@f-sg.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Herminia Esteban, BD</last_name>
    <phone>00340915568025</phone>
    <email>hesteban@f-sg.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>H. Álvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Antonio Ocampo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. de Elche</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Félix Gutierrez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. General de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Joaquín Portilla, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Arkaitz Imaz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jose Luis Blanco, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Hernando Knobel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUAC</name>
      <address>
        <city>Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Álvaro Mena, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. de Donosti</name>
      <address>
        <city>Donostia</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jose A Iribarren, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Fundación Jimenez Díaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Alfonso Cabello, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jesús Troya, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jesús Sanz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Príncipe de Asturias</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Cristina Hernandez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Severo Ochoa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Miguel Cervero, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>María De Lagarde, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Univ. Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Juan Carlos Lopez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jose Ramón Arribas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jesús Santos, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

